{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:10:45Z","timestamp":1790766645426,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM121334"],"award-info":[{"award-number":["P20GM121334"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM104357"],"award-info":[{"award-number":["P20GM104357"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R21DK113500"],"award-info":[{"award-number":["R21DK113500"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["F30DK127527"],"award-info":[{"award-number":["F30DK127527"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["P01HL51971"],"award-info":[{"award-number":["P01HL51971"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["903804"],"award-info":[{"award-number":["903804"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Sex Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS), characterized by androgen excess and ovulatory dysfunction, is associated with a high prevalence of obesity and insulin resistance (IR) in women. We demonstrated that sodium\u2013glucose cotransporter-2 inhibitor (SGLT2i) administration decreases fat mass without affecting IR in the PCOS model. In male models of IR, administration of SGLT2i decreases oxidative stress and improves mitochondrial function in white adipose tissue (WAT). Therefore, we hypothesized that SGLT2i reduces adiposity via improvement in mitochondrial function and oxidative stress in WAT in PCOS model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four-week-old female rats were treated with dihydrotestosterone for 90\u00a0days (PCOS model), and SGLT2i (empagliflozin) was co-administered during the last 3\u00a0weeks. Body composition was measured before and after SGLT2i treatment by EchoMRI. Subcutaneous (SAT) and visceral (VAT) WAT were collected for histological and molecular studies at the end of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PCOS model had an increase in food intake, body weight, body mass index, and fat mass\/lean mass ratio compared to the control group. SGLT2i lowered fat mass\/lean ratio in PCOS. Glucosuria was observed in both groups, but had a larger magnitude in controls. The net glucose balance was similar in both SGLT2i-treated groups. The PCOS SAT had a higher frequency of small adipocytes and a lower frequency of large adipocytes. In SAT of controls, SGLT2i increased frequencies of small and medium adipocytes while decreasing the frequency of large adipocytes, and this effect was blunted in PCOS. In VAT, PCOS had a lower frequency of small adipocytes while SGLT2i increased the frequency of small adipocytes in PCOS. PCOS model had decreased mitochondrial content in SAT and VAT without impacting oxidative stress in WAT or the circulation. SGLT2i did not modify mitochondrial function or oxidative stress in WAT in both treated groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hyperandrogenemia in PCOS causes expansion of WAT, which is associated with decreases in mitochondrial content and function in SAT and VAT. SGLT2i increases the frequency of small adipocytes in VAT only without affecting mitochondrial dysfunction, oxidative stress, or IR in the PCOS model. SGLT2i decreases adiposity independently of adipose mitochondrial and oxidative stress mechanisms in the PCOS model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13293-022-00455-x","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T04:03:58Z","timestamp":1660881838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition"],"prefix":"10.1186","volume":"13","author":[{"given":"Jacob E.","family":"Pruett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Everman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc H.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faridah","family":"Salau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin S.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Hosler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian G.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-1871","authenticated-orcid":false,"given":"Licy L.","family":"Yanes Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"issue":"12","key":"455_CR1","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/humrep\/dew218","volume":"31","author":"G Bozdag","year":"2016","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841\u201355.","journal-title":"Hum Reprod"},{"issue":"2","key":"455_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dep399","volume":"25","author":"WA March","year":"2010","unstructured":"March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544\u201351.","journal-title":"Hum Reprod"},{"issue":"9","key":"455_CR3","first-page":"3078","volume":"83","author":"ES Knochenhauer","year":"1998","unstructured":"Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"455_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/er.2015-1018","volume":"36","author":"DA Dumesic","year":"2015","unstructured":"Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487\u2013525.","journal-title":"Endocr Rev"},{"issue":"4","key":"455_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1210\/jc.2005-2430","volume":"91","author":"JC Lo","year":"2006","unstructured":"Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(4):1357\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"455_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/humrep\/16.3.556","volume":"16","author":"MW Elting","year":"2001","unstructured":"Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001;16(3):556\u201360.","journal-title":"Hum Reprod"},{"issue":"16","key":"455_CR7","doi-asserted-by":"publisher","first-page":"e14219","DOI":"10.14814\/phy2.14219","volume":"7","author":"Y Song","year":"2019","unstructured":"Song Y, Ye W, Ye H, Xie T, Shen W, Zhou L. Serum testosterone acts as a prognostic indicator in polycystic ovary syndrome-associated kidney injury. Physiol Rep. 2019;7(16):e14219.","journal-title":"Physiol Rep"},{"key":"455_CR8","doi-asserted-by":"publisher","first-page":"719050","DOI":"10.1155\/2014\/719050","volume":"2014","author":"J Rojas","year":"2014","unstructured":"Rojas J, Chavez M, Olivar L, Rojas M, Morillo J, Mejias J, Calvo M, Bermudez V. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014;2014:719050.","journal-title":"Int J Reprod Med"},{"issue":"2","key":"455_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1210\/jc.2003-031122","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Sanchez L, Knochenhauer E, Moran C, Lazenby J, Stephens K, Taylor K, Boots L. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"455_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMcp1514916","volume":"375","author":"CR McCartney","year":"2016","unstructured":"McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome. N Engl J Med. 2016;375(1):54\u201364.","journal-title":"N Engl J Med"},{"issue":"6","key":"455_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/cen.13968","volume":"90","author":"Z Javed","year":"2019","unstructured":"Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, Khan AY, Kilpatrick ES, Atkin SL, Sathyapalan T. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clin Endocrinol (Oxf). 2019;90(6):805\u201313.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"455_CR12","doi-asserted-by":"publisher","first-page":"e21945","DOI":"10.1096\/fj.202002526RR","volume":"35","author":"LL Yanes Cardozo","year":"2021","unstructured":"Yanes Cardozo LL, Romero DG. Management of cardiometabolic complications in polycystic ovary syndrome: unmet needs. FASEB J. 2021;35(11):e21945.","journal-title":"FASEB J"},{"issue":"2","key":"455_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.genm.2010.11.013","volume":"8","author":"LL Yanes","year":"2011","unstructured":"Yanes LL, Romero DG, Moulana M, Lima R, Davis DD, Zhang H, Lockhart R, Racusen LC, Reckelhoff JF. Cardiovascular-renal and metabolic characterization of a rat model of polycystic ovary syndrome. Gend Med. 2011;8(2):103\u201315.","journal-title":"Gend Med"},{"issue":"5","key":"455_CR14","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.3390\/ijms22052576","volume":"22","author":"JE Pruett","year":"2021","unstructured":"Pruett JE, Torres Fernandez ED, Everman SJ, Vinson RM, Davenport K, Logan MK, Ye SA, Romero DG, Yanes Cardozo LL. Impact of SGLT-2 inhibition on cardiometabolic abnormalities in a rat model of polycystic ovary syndrome. Int J Mol Sci. 2021;22(5):2576.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"455_CR15","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1210\/en.2015-1617","volume":"157","author":"C Dalmasso","year":"2016","unstructured":"Dalmasso C, Maranon R, Patil C, Bui E, Moulana M, Zhang H, Smith A, Yanes Cardozo LL, Reckelhoff JF. Cardiometabolic effects of chronic hyperandrogenemia in a new model of postmenopausal polycystic ovary syndrome. Endocrinology. 2016;157(7):2920\u20137.","journal-title":"Endocrinology"},{"issue":"8","key":"455_CR16","doi-asserted-by":"publisher","first-page":"R708","DOI":"10.1152\/ajpregu.00411.2014","volume":"308","author":"R Maranon","year":"2015","unstructured":"Maranon R, Lima R, Spradley FT, do Carmo JM, Zhang H, Smith AD, Bui E, Thomas RL, Moulana M, Hall JE. Roles for the sympathetic nervous system, renal nerves, and CNS melanocortin-4 receptor in the elevated blood pressure in hyperandrogenemic female rats. Am J Physiol Regul Integr Comp Physiol. 2015;308(8):R708\u201313.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"455_CR17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.2337\/db17-1032","volume":"67","author":"Y Okuno","year":"2018","unstructured":"Okuno Y, Fukuhara A, Hashimoto E, Kobayashi H, Kobayashi S, Otsuki M, Shimomura I. Oxidative stress inhibits healthy adipose expansion through suppression of SREBF1-mediated lipogenic pathway. Diabetes. 2018;67(6):1113\u201327.","journal-title":"Diabetes"},{"issue":"2","key":"455_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1113\/jphysiol.2003.049478","volume":"552","author":"JF Turrens","year":"2003","unstructured":"Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552(2):335\u201344.","journal-title":"J Physiol"},{"issue":"1","key":"455_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yexmp.2006.09.008","volume":"83","author":"SR Pieczenik","year":"2007","unstructured":"Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol. 2007;83(1):84\u201392.","journal-title":"Exp Mol Pathol"},{"issue":"4","key":"455_CR20","first-page":"35","volume":"13","author":"GL Nicolson","year":"2014","unstructured":"Nicolson GL. Mitochondrial dysfunction and chronic disease: treatment with natural supplements. Integr Med Clin J. 2014;13(4):35.","journal-title":"Integr Med Clin J"},{"issue":"12","key":"455_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.metabol.2011.04.010","volume":"60","author":"S-H Lee","year":"2011","unstructured":"Lee S-H, Chung D-J, Lee H-S, Kim T-J, Kim M-H, Jeong HJ, Im J-A, Lee D-C, Lee J-W. Mitochondrial DNA copy number in peripheral blood in polycystic ovary syndrome. Metabolism. 2011;60(12):1677\u201382.","journal-title":"Metabolism"},{"key":"455_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mito.2017.12.010","volume":"44","author":"TV Reddy","year":"2019","unstructured":"Reddy TV, Govatati S, Deenadayal M, Sisinthy S, Bhanoori M. Impact of mitochondrial DNA copy number and displacement loop alterations on polycystic ovary syndrome risk in south Indian women. Mitochondrion. 2019;44:35\u201340.","journal-title":"Mitochondrion"},{"issue":"3","key":"455_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1530\/EC-19-0553","volume":"9","author":"NR Chappell","year":"2020","unstructured":"Chappell NR, Zhou B, Schutt AK, Gibbons WE, Blesson CS. Prenatal androgen induced lean PCOS impairs mitochondria and mRNA profiles in oocytes. Endocr Connect. 2020;9(3):261\u201370.","journal-title":"Endocr Connect"},{"issue":"4","key":"455_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-201X.2004.01370.x","volume":"182","author":"ME Harper","year":"2004","unstructured":"Harper ME, Bevilacqua L, Hagopian K, Weindruch R, Ramsey JJ. Ageing, oxidative stress, and mitochondrial uncoupling. Acta Physiol Scand. 2004;182(4):321\u201331.","journal-title":"Acta Physiol Scand"},{"key":"455_CR25","doi-asserted-by":"publisher","first-page":"360438","DOI":"10.1155\/2014\/360438","volume":"2014","author":"A Ayala","year":"2014","unstructured":"Ayala A, Mu\u00f1oz MF, Arg\u00fcelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438.","journal-title":"Oxid Med Cell Longev"},{"key":"455_CR26","doi-asserted-by":"publisher","first-page":"105728","DOI":"10.1016\/j.jsbmb.2020.105728","volume":"203","author":"SC Magalh\u00e3es","year":"2020","unstructured":"Magalh\u00e3es SC, de Oliveira KA, Freiras PA, Gomes MDM, Pereira LM, Boa LF, de Carvalho DP, Fortunato RS, Loureiro ACC, Brito LC. High-dose Nandrolone Decanoate induces oxidative stress and inflammation in retroperitoneal adipose tissue of male rats. J Steroid Biochem Mol Biol. 2020;203:105728.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"12","key":"455_CR27","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1093\/humrep\/dei258","volume":"20","author":"M Yilmaz","year":"2005","unstructured":"Yilmaz M, Bukan N, Ayvaz GK, Karako\u00e7 A, Toruner F, \u00c7akir N, Arslan M. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20(12):3333\u201340.","journal-title":"Hum Reprod"},{"issue":"8","key":"455_CR28","doi-asserted-by":"publisher","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","volume":"302","author":"I Sabolic","year":"2012","unstructured":"Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H. Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol. 2012;302(8):C1174-1188.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"455_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2337\/dbi18-0007","volume":"68","author":"RZ Alicic","year":"2019","unstructured":"Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes. 2019;68(2):248\u201357.","journal-title":"Diabetes"},{"issue":"22","key":"455_CR30","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"455_CR31","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"15","key":"455_CR32","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJ Heerspink","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JF, McMurray JJ, Lindberg M, Rossing P. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"455_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/21623945.2020.1807850","volume":"9","author":"X Yang","year":"2020","unstructured":"Yang X, Liu Q, Li Y, Tang Q, Wu T, Chen L, Pu S, Zhao Y, Zhang G, Huang C. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1\u03b1 signalling pathway. Adipocyte. 2020;9(1):484\u201394.","journal-title":"Adipocyte"},{"key":"455_CR34","doi-asserted-by":"publisher","first-page":"117414","DOI":"10.1016\/j.lfs.2020.117414","volume":"247","author":"D Wei","year":"2020","unstructured":"Wei D, Liao L, Wang H, Zhang W, Wang T, Xu Z. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro. Life Sci. 2020;247:117414.","journal-title":"Life Sci"},{"key":"455_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","volume":"100","author":"JC Corona","year":"2016","unstructured":"Corona JC, Duchen MR. PPAR\u03b3 as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med. 2016;100:153\u201363.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"455_CR36","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1074\/jbc.M707587200","volume":"283","author":"SS Dhar","year":"2008","unstructured":"Dhar SS, Ongwijitwat S, Wong-Riley MT. Nuclear respiratory factor 1 regulates all ten nuclear-encoded subunits of cytochrome c oxidase in neurons. J Biol Chem. 2008;283(6):3120\u20139.","journal-title":"J Biol Chem"},{"issue":"5","key":"455_CR37","doi-asserted-by":"publisher","first-page":"R816","DOI":"10.1152\/ajpregu.00520.2016","volume":"312","author":"JD Warfel","year":"2017","unstructured":"Warfel JD, Vandanmagsar B, Dubuisson OS, Hodgeson SM, Elks CM, Ravussin E, Mynatt RL. Examination of carnitine palmitoyltransferase 1 abundance in white adipose tissue: implications in obesity research. Am J Physiol-Regul Integr Comp Physiol. 2017;312(5):R816\u201320.","journal-title":"Am J Physiol-Regul Integr Comp Physiol"},{"issue":"4","key":"455_CR38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000499597","volume":"49","author":"TC Woods","year":"2019","unstructured":"Woods TC, Satou R, Miyata K, Katsurada A, Dugas CM, Klingenberg NC, Fonseca VA, Navar LG. Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in Mouse Model of Type 2 Diabetes Mellitus. Am J Nephrol. 2019;49(4):331\u201342.","journal-title":"Am J Nephrol"},{"key":"455_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S, Oelze M, Hanf A, Kroller-Schon S, Kashani F, Roohani S, Welschof P, Kopp M, Godtel-Armbrust U, Xia N, Li H, Schulz E, Lackner KJ, Wojnowski L, Bottari SP, Wenzel P, Mayoux E, Munzel T, Daiber A. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370\u201385.","journal-title":"Redox Biol"},{"key":"455_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fendo.2016.00030","volume":"7","author":"SS Choe","year":"2016","unstructured":"Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose tissue remodeling: its role in energy metabolism and metabolic disorders. Front Endocrinol. 2016;7:30.","journal-title":"Front Endocrinol"},{"key":"455_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/B978-0-12-411619-1.00006-9","volume":"537","author":"SD Parlee","year":"2014","unstructured":"Parlee SD, Lentz SI, Mori H, MacDougald OA. Quantifying size and number of adipocytes in adipose tissue. Methods Enzymol. 2014;537:93\u2013122.","journal-title":"Methods Enzymol"},{"issue":"12","key":"455_CR42","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1194\/jlr.D023788","volume":"53","author":"M Galarraga","year":"2012","unstructured":"Galarraga M, Campi\u00f3n J, Mu\u00f1oz-Barrutia A, Boqu\u00e9 N, Moreno H, Mart\u00ednez JA, Milagro F, Ortiz-de-Sol\u00f3rzano C. Adiposoft: automated software for the analysis of white adipose tissue cellularity in histological sections. J Lipid Res. 2012;53(12):2791\u20136.","journal-title":"J Lipid Res"},{"issue":"14","key":"455_CR43","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1113\/jphysiol.2012.230185","volume":"590","author":"S Larsen","year":"2012","unstructured":"Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, Schroder HD, Boushel R, Helge JW, Dela F. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiol. 2012;590(14):3349\u201360.","journal-title":"J Physiol"},{"issue":"6","key":"455_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-018-0707-9","volume":"113","author":"KS Edwards","year":"2018","unstructured":"Edwards KS, Ashraf S, Lomax TM, Wiseman JM, Hall ME, Gava FN, Hall JE, Hosler JP, Harmancey R. Uncoupling protein 3 deficiency impairs myocardial fatty acid oxidation and contractile recovery following ischemia\/reperfusion. Basic Res Cardiol. 2018;113(6):1\u201316.","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"455_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cmet.2015.06.022","volume":"22","author":"LS Sidossis","year":"2015","unstructured":"Sidossis LS, Porter C, Saraf MK, B\u00f8rsheim E, Radhakrishnan RS, Chao T, Ali A, Chondronikola M, Mlcak R, Finnerty CC. Browning of subcutaneous white adipose tissue in humans after severe adrenergic stress. Cell Metab. 2015;22(2):219\u201327.","journal-title":"Cell Metab"},{"issue":"46","key":"455_CR46","doi-asserted-by":"publisher","first-page":"17669","DOI":"10.1074\/jbc.RA119.010317","volume":"294","author":"NH Hoang","year":"2019","unstructured":"Hoang NH, Strogolova V, Mosley JJ, Stuart RA, Hosler J. Hypoxia-inducible gene domain 1 proteins in yeast mitochondria protect against proton leak through complex IV. J Biol Chem. 2019;294(46):17669\u201377.","journal-title":"J Biol Chem"},{"issue":"2","key":"455_CR47","first-page":"604","volume":"102","author":"M Gibson-Helm","year":"2017","unstructured":"Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(2):604\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"455_CR48","first-page":"1","volume":"18","author":"E Chang","year":"2018","unstructured":"Chang E, Varghese M, Singer K. Gender and sex differences in adipose tissue. Curr DiabRep. 2018;18(9):1\u201310.","journal-title":"Curr DiabRep"},{"issue":"3","key":"455_CR49","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1210\/jc.2007-2117","volume":"93","author":"TM Barber","year":"2008","unstructured":"Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, McCarthy MI. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(3):999\u20131004.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"455_CR50","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4103\/ijem.IJEM_646_17","volume":"22","author":"D Jena","year":"2018","unstructured":"Jena D, Choudhury AK, Mangaraj S, Singh M, Mohanty BK, Baliarsinha AK. Study of visceral and subcutaneous abdominal fat thickness and its correlation with cardiometabolic risk factors and hormonal parameters in polycystic ovary syndrome. Indian J Endocrinol Metab. 2018;22(3):321.","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"455_CR51","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/humrep\/der070","volume":"26","author":"JG Dolfing","year":"2011","unstructured":"Dolfing JG, Stassen CM, van Haard PM, Wolffenbuttel BH, Schweitzer DH. Comparison of MRI-assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS. Hum Reprod. 2011;26(6):1495\u2013500.","journal-title":"Hum Reprod"},{"issue":"12","key":"455_CR52","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1210\/en.2019-00450","volume":"160","author":"ED Torres Fernandez","year":"2019","unstructured":"Torres Fernandez ED, Huffman AM, Syed M, Romero DG, Yanes Cardozo LL. Effect of GLP-1 receptor agonists in the cardiometabolic complications in a rat model of postmenopausal PCOS. Endocrinology. 2019;160(12):2787\u201399.","journal-title":"Endocrinology"},{"issue":"8","key":"455_CR53","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1210\/en.2007-0168","volume":"148","author":"L Manneras","year":"2007","unstructured":"Manneras L, Cajander S, Holm\u00e4ng A, Seleskovic Z, Lystig T, L\u00f6nn M, Stener-Victorin E. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007;148(8):3781\u201391.","journal-title":"Endocrinology"},{"issue":"11","key":"455_CR54","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1210\/jc.2016-2586","volume":"101","author":"DA Dumesic","year":"2016","unstructured":"Dumesic DA, Akopians AL, Madrigal VK, Ramirez E, Margolis DJ, Sarma MK, Thomas AM, Grogan TR, Haykal R, Schooler TA. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 2016;101(11):4178\u201388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"455_CR55","doi-asserted-by":"publisher","first-page":"R284","DOI":"10.1152\/ajpregu.00257.2017","volume":"315","author":"KG Stenkula","year":"2018","unstructured":"Stenkula KG, Erlanson-Albertsson C. Adipose cell size: importance in health and disease. Am J Physiol-Regul Integr Comp Physiol. 2018;315(2):R284\u201395.","journal-title":"Am J Physiol-Regul Integr Comp Physiol"},{"key":"455_CR56","doi-asserted-by":"publisher","first-page":"111137","DOI":"10.1016\/j.mce.2020.111137","volume":"523","author":"J Dou","year":"2021","unstructured":"Dou J, Puttabyatappa M, Padmanabhan V, Bakulski KM. Developmental programming: adipose depot-specific transcriptional regulation by prenatal testosterone excess in a sheep model of PCOS. Mol Cell Endocrinol. 2021;523:111137.","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"455_CR57","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity. 2012;20(8):1645\u201352.","journal-title":"Obesity"},{"key":"455_CR58","doi-asserted-by":"crossref","unstructured":"Milatovic D, Montine TJ, Aschner M. Measurement of isoprostanes as markers of oxidative stress. In: In vitro neurotoxicology. Springer; 2011:195\u2013204.","DOI":"10.1007\/978-1-61779-170-3_13"},{"issue":"13","key":"455_CR59","doi-asserted-by":"publisher","first-page":"e019995","DOI":"10.1161\/JAHA.120.019995","volume":"10","author":"D Croteau","year":"2021","unstructured":"Croteau D, Luptak I, Chambers JM, Hobai I, Panagia M, Pimentel DR, Siwik DA, Qin F, Colucci WS. Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice. J Am Heart Assoc. 2021;10(13):e019995.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"455_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, Zhao J, Zhao Y, Li G, Liu T. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18(1):1\u201314.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"455_CR61","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jdi.12802","volume":"9","author":"S Takagi","year":"2018","unstructured":"Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T, Kanasaki K, Koya D. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig. 2018;9(5):1025\u201332.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"455_CR62","doi-asserted-by":"publisher","first-page":"e018298","DOI":"10.1161\/JAHA.120.018298","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, Mouton A, Omoto AC, Hall ME, Li J. Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure. J Am Heart Assoc. 2021;10(6):e018298.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"455_CR63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp D, Bakker R, Mark M, Klein T, Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"455_CR64","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","volume":"115","author":"L Uthman","year":"2019","unstructured":"Uthman L, Nederlof R, Eerbeek O, Baartscheer A, Schumacher C, Buchholtz N, Hollmann MW, Coronel R, Weber NC, Zuurbier CJ. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc Res. 2019;115(10):1533\u201345.","journal-title":"Cardiovasc Res"},{"issue":"14","key":"455_CR65","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1093\/cvr\/cvab129","volume":"117","author":"CJ Zuurbier","year":"2021","unstructured":"Zuurbier CJ, Baartscheer A, Schumacher CA, Fiolet JW, Coronel R. Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+\/H+ exchanger 1: persistent inhibition under various experimental conditions. Cardiovasc Res. 2021;117(14):2699\u2013701.","journal-title":"Cardiovasc Res"},{"key":"455_CR66","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021;83:503\u201328.","journal-title":"Annu Rev Physiol"},{"issue":"9","key":"455_CR67","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00424-020-02417-x","volume":"472","author":"A Chadt","year":"2020","unstructured":"Chadt A, Al-Hasani H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pfl\u00fcgers Archiv-Eur J Physiol. 2020;472(9):1273\u201398.","journal-title":"Pfl\u00fcgers Archiv-Eur J Physiol"}],"container-title":["Biology of Sex Differences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13293-022-00455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13293-022-00455-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13293-022-00455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:11:01Z","timestamp":1668694261000},"score":1,"resource":{"primary":{"URL":"https:\/\/bsd.biomedcentral.com\/articles\/10.1186\/s13293-022-00455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1186\/s13293-022-00455-x","relation":{},"ISSN":["2042-6410"],"issn-type":[{"value":"2042-6410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were performed following the National Institutes of Health Guide for the Care and Use of Laboratory Animals, 8th Edition, 2011, and approved by the Institutional Animal Care and Use Committee of the University of Mississippi Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LLYC is an Associate Editor of <i>Biology of Sex Differences.<\/i> No other conflicts of interest, financial or otherwise, are declared by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}